|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Daiichi_Pharmaceutical
gptkb:Ranbaxy_Laboratories
gptkb:Sankyo_Company,_Limited
|
|
gptkbp:awards
|
Top 100 Global Innovators 2020
Best Workplaces 2021
Pharma Awards 2019
|
|
gptkbp:ceo
|
gptkb:Seigo_Kikuchi
gptkb:J._Scott_Mc_Culloch
|
|
gptkbp:clinical_trial
|
Ongoing
ongoing
Phase III trials
Phase I trials
Phase II trials
|
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:University_of_Tokyo
|
|
gptkbp:employees
|
approximately 15,000
|
|
gptkbp:focus_area
|
gptkb:Biosimilars
Generic drugs
Innovative medicines
|
|
gptkbp:founded
|
gptkb:2005
|
|
gptkbp:founder
|
gptkb:Daiichi_Pharmaceutical
|
|
gptkbp:global_presence
|
Over 20 countries
over 20 countries
|
|
gptkbp:headcount
|
15,000+
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
gptkb:Minato,_Tokyo
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo Group
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
Pharmaceuticals
|
|
gptkbp:instruction_set
|
over 20 candidates
|
|
gptkbp:investment
|
R& D investment of $1.5 billion (2020)
|
|
gptkbp:market_cap
|
$40 billion (2021)
|
|
gptkbp:number_of_employees
|
around 15,000
|
|
gptkbp:parent_company
|
gptkb:Daiichi_Sankyo_Company,_Limited
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:pharmaceuticals
gptkb:Johnson_&_Johnson
gptkb:Aurobindo_Pharma
gptkb:Takeda_Pharmaceutical_Company
gptkb:Mylan
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Intas_Pharmaceuticals
gptkb:Amgen
gptkb:Sandoz
gptkb:Hikma_Pharmaceuticals
gptkb:Astellas_Pharma
gptkb:Eli_Lilly_and_Company
gptkb:Vertex_Pharmaceuticals
gptkb:Lupin_Pharmaceuticals
gptkb:Sun_Pharmaceutical_Industries
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Novartis
gptkb:Zydus_Cadila
gptkb:Dr._Reddy's_Laboratories
gptkb:Cadila_Healthcare
|
|
gptkbp:partnerships
|
alliances with research institutions
collaborations with biotech firms
joint ventures in Asia
|
|
gptkbp:pharmaceutical_research
|
gptkb:gene_therapy
biologics
small molecules
|
|
gptkbp:philanthropy
|
gptkb:Daiichi_Sankyo_Foundation_of_Life_Science
|
|
gptkbp:products
|
vaccines
Cardiovascular drugs
oncology drugs
cardiovascular drugs
Anticancer agents
|
|
gptkbp:research_areas
|
gptkb:diabetes
neurology
pain management
|
|
gptkbp:research_focus
|
gptkb:Cardiovascular_diseases
gptkb:Oncology
Infectious diseases
oncology
cardiovascular diseases
infectious diseases
pain management
cardiovascular
|
|
gptkbp:revenue
|
$10 billion (2020)
$10.5 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stock_symbol
|
4568
4568. T
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo_Europe_Gmb_H
gptkb:Daiichi_Sankyo,_Inc.
|
|
gptkbp:sustainability_initiatives
|
community engagement
ethical sourcing
environmental responsibility
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.daiichisankyo.com
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo_Europe_Gmb_H
|
|
gptkbp:bfsLayer
|
6
|